Steven M. Paul

Last updated

Steven M. Paul is an American neuroscientist and pharmaceutical executive. Paul was the former CEO, president, and chairman of Karuna Therapeutics. [1]

Contents

Career

Paul received his bachelor's, master's, and medical degree from Tulane University. [2] Following a residency in psychiatry at the University of Chicago, he joined the National Institute of Mental Health (NIMH) in 1976. In 1982, Paul and his colleague, Phil Skolnick, published their discovery that the ethyl ester of beta carboline-3-carboxylic acid (beta-CCE) triggered anxiety in people; the work was recognized as an example of the growing ability of neuroscientists to understand the biochemistry of emotions. [3] In 1989, he was the senior scientist on a paper published in Nature that undercut the claim that mutations in a gene on chromosome 11 caused bipolar disorder, which previously had been hailed as evidence that studies of genetics would lead to definitive biomarkers for mental illnesses. [4] Around this time, he became the scientific director of intramural research at NIMH. [5]

Paul moved to Eli Lilly and Company in 1993 as vice president for central nervous system discovery research and decision-phase medical research. [5] He was described by a New York Times reporter in 1996 as being "one of those at the forefront of the development of the coming breed of psychiatric medications." [5] In 1998 he was named group vice president, therapeutic area discovery research and clinical investigation, and by 2003 he was Lilly's executive vice president for science and technology and president of Lilly Research Laboratories. [6] He helped organize cooperation and funding from pharmaceutical companies in establishing the Alzheimer's Disease Neuroimaging Initiative, a non-proprietary collaborative research effort to establish imaging biomarkers for Alzheimer's disease. [7]

In the early 2000s, Paul helped lead the company toward a new model of drug discovery and development that focused on getting proof of concept as early as possible in the research process, in order to avoid failures in Phase II clinical trials. [8] [9] As part of that effort he helped establish Lilly Chorus, an autonomous business unit that was created to design and execute studies that would allow drug candidates to "fail early" instead of lingering in a company's pipeline. [10] [11] [12] [13] He also led Lilly's work on Alzheimer's drugs, which however dramatically failed in Phase III clinical trials. [14] [15] Paul is also an adjunct professor of psychiatry and neurology at Washington University of St. Louis School of Medicine. [16] [17]

Boards and memberships

Paul is a member of the National Academy of Sciences and the National Academy of Medicine. [18]

As of 2017 he was on the board of directors for Butler University, the Foundation for the National Institutes of Health, and the Eli Lilly & Co. Foundation. [18] As of 2017 he was also on the board of directors of Alnylam, SAGE Therapeutics, Tal Medical, Sigma-Aldrich, Karuna Therapeutics, Voyager Therapeutics, Constellation Pharmaceuticals, the Biotechnology Industry Organization, and DemeRx. [18]

He is also an elected fellow emeritus of the American College of Neuropsychopharmacology (ACNP) and served as ACNP President (1999). [19] [20] As of 2020, he was on the board of directors or is a trustee of several organizations, including serving as chairman of the Board of the Foundation for the NIH (FNIH) [21] and as a Director of Alnylam Pharmaceuticals, [22] Sage Therapeutics, [23] Voyager Therapeutics [24] and Karuna Pharmaceuticals. [25] He has also served as a member of the National Institute of General Medical Sciences (NIGMS) [19]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Eli Lilly and Company</span> American pharmaceutical company

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War for whom the company was later named.

Robert R. Ruffolo was president of research and development for Wyeth Pharmaceuticals, and corporate senior vice president of Wyeth from 2001 to 2008. In that role, he managed an R&D organization of 7,000 scientists, with an annual budget of $3 billion. During his career in the pharmaceutical industry, Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including dobutamine (Dobutrex) for the acute management of congestive heart failure, and eprosartan (Teveten) for hypertension. He holds the patent for the discovery of use of carvedilol (Coreg) for the treatment of congestive heart failure which changed the paradigm for the treatment of this devastating disease, and he led the research team that discovered ropinerole (Requip) for Parkinson's Disease. Ruffolo was awarded the Discoverers Award in 2008 by the Pharmaceutical Research and Manufacturers Association (PhRMA), for his pioneering work on the discovery of carvedilol for congestive heart failure.

Sir Menelaos (Mene) Nicolas Pangalos is a British neuroscientist of Greek descent.

Frederick King Goodwin was an American psychiatrist and Clinical Professor of Psychiatry at the George Washington University Medical Center, where he was also director of the Center on Neuroscience, Medical Progress, and Society. He was a specialist in bipolar disorder and recurrent depression.

<span class="mw-page-title-main">Xanomeline</span> Chemical compound

Xanomeline is a small molecule muscarinic acetylcholine receptor agonist that was first synthesized in a collaboration between Eli Lilly and Novo Nordisk as an investigational therapeutic being studied for the treatment of central nervous system disorders.

Steven Edward Hyman is Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts. He is also Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Hyman was Provost of Harvard University from 2001 to 2011 and before that Director of the U.S. National Institute of Mental Health (NIMH) from 1996 to 2001. Hyman received the 2016 Rhoda and Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine for "leadership in furthering understanding and treatment of psychiatric disorders as biological diseases".

<span class="mw-page-title-main">National Organization for Rare Disorders</span> U.S. nonprofit organization

The National Organization for Rare Disorders (NORD) is a nonprofit organization, based in Connecticut, aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Marc Tessier-Lavigne</span> Canadian neuroscientist (born 1959)

Marc Trevor Tessier-Lavigne is a Canadian-American neuroscientist who was the eleventh president of Stanford University.

John C. Lechleiter is an American businessman and chemist. He served as president, chief executive officer, and chairman of the board of directors of Eli Lilly and Company from April 2008 to December 2016.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Phil Skolnick is an American neuroscientist and pharmacologist most widely known for his work on the psychopharmacology of depression and anxiety, as well as on addiction medicine. Author of more than 500 published papers, Skolnick's most notable accomplishments include elucidating the role of the NMDA system in depression therapeutics, demonstrating the existence of endogenous benzodiazepine receptor ligands, and spearheading the National Institute on Drug Abuse's partnership to develop a naloxone atomizer for reversal of acute opioid overdose. Skolnick's work also laid the foundation for the development of ketamine as a rapid-acting antidepressant.

Paul Stephen Aisen is an American physician and medical researcher. He started his career as a rheumatologist and then made Alzheimer's disease his focus.

Jonathan Otis Cole was an American psychiatrist and the former chief of psychopharmacology at McLean Hospital. He was considered to be the “father of clinical psychopharmacology in the United States [...] internationally known for his breakthrough research on the use of drugs to treat psychiatric illnesses.”

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.

Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019.

Xanomeline/trospium, also known under the brand name KarXT, is an investigational oral dual-drug fixed-dose combination of xanomeline and trospium. It is undergoing a phase 3 clinical trial for the treatment of schizophrenia. Xanomeline is a functionally preferring muscarinic M4 and M1 receptor agonist that readily passes into the central nervous system (CNS) to stimulate these receptors in key areas of the brain. Trospium is a non-selective muscarinic antagonist that does not cross into the CNS and reduces peripheral cholinergic side effects associated with xanomeline.

Michelle R. Arkin is an American chemical biologist who is the Thomas William and Frederick John MacWilliam Distinguished Professor at the University of California, San Francisco (UCSF).

References

  1. ↑ "Where Are They Now? Karuna Therapeutics". www.lifescienceleader.com. Retrieved 2024-01-27.
  2. ↑ "Neuroscientist, pharmaceutical executive Dr. Steven Paul named to Board of Tulane | Tulane University News". news.tulane.edu. 6 July 2018. Retrieved 2024-01-30.
  3. ↑ Schmeck, Jr, Harold M. (7 September 1982). "The Biology of Fear and Anxiety: Evidence Points to Chemical Triggers". The New York Times.
  4. ↑ Schmeck, Harold M. Jr. (7 November 1989). "Scientists Now Doubt They Found Faulty Gene Linked to Mental Illness". The New York Times.
  5. 1 2 3 Goleman, Daniel (19 November 1996). "Research on Brain Leads to Pursuit Of Designer Drugs". The New York Times.
  6. ↑ Harris, Gardiner (22 November 2003). "Cialis, Lilly's Entry in Impotence Market, Is Approved". The New York Times.
  7. ↑ Kolata, Gina (12 August 2010). "Rare Sharing of Data Led to Results on Alzheimer's". The New York Times.
  8. ↑ Berenson, Alex (3 July 2005). "Blockbuster Drugs Are So Last Century". The New York Times.
  9. ↑ Paul, SM; Mytelka, DS; Dunwiddie, CT; Persinger, CC; Munos, BH; Lindborg, SR; Schacht, AL (March 2010). "How to improve R&D productivity: the pharmaceutical industry's grand challenge". Nature Reviews. Drug Discovery. 9 (3): 203–14. doi: 10.1038/nrd3078 . PMID   20168317.
  10. ↑ Bonabeau, E; Bodick, N; Armstrong, RW (March 2008). "A more rational approach to new-product development". Harvard Business Review. 86 (3): 96–102, 134. PMID   18411967.
  11. ↑ Paul, S. (January 2009). "An Audience with: Steven Paul". Nature Reviews. Drug Discovery. 8 (1): 14. doi: 10.1038/nrd2800 . PMID   19116623. S2CID   21916329.
  12. ↑ Henderson, Rebecca; Reavis, Cate (March 13, 2008). "Eli Lilly: Recreating Drug Discovery for the 21st Century" (PDF). MIT Sloan School of Management.
  13. ↑ Owens, PK; Raddad, E; Miller, JW; Stille, JR; Olovich, KG; Smith, NV; Jones, RS; Scherer, JC (January 2015). "A decade of innovation in pharmaceutical R&D: the Chorus model". Nature Reviews. Drug Discovery. 14 (1): 17–28. doi:10.1038/nrd4497. PMID   25503514. S2CID   8067609.
  14. ↑ Wall, J.K. (August 11, 2012). "Alzheimer's quest puts Lilly to test". Indiana Business Journal.
  15. ↑ Taylor, Phil (November 23, 2016). "Alzheimer's hopes dashed as Lilly gives up on amyloid drug solanezumab". FierceBiotech.
  16. ↑ "Steve Paul". Thirdrockventures. Retrieved 2024-01-30.
  17. ↑ "Steven Paul". Research Profiles at Washington University School of Medicine. Retrieved 2024-01-30.
  18. 1 2 3 "Paul profile as Alnyam Board Member". Wall Street Journal. Retrieved 1 March 2017.
  19. 1 2 "CURRICULUM VITAE STEVEN MARC PAUL, M.D". Food and Drug Administration . Archived from the original on March 6, 2021.
  20. ↑ https://www.cipherbio.com/data-viz/person/24044/Steven%2BPaul [ bare URL ]
  21. ↑ "Steven M. Paul, M.D. | the Foundation for the National Institutes of Health".
  22. ↑ "The Alnylam® Leadership Team". www.alnylam.com.
  23. ↑ "Steven Paul, M.D. | Board of Directors | Sage Therapeutics, Inc".
  24. ↑ "Voyager Therapeutics".
  25. ↑ "About Us • Karuna". Karuna.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.